JP2011515412A - Ｈｉｖインテグラーゼ阻害剤としての架橋ヘテロ環 - Google Patents
Ｈｉｖインテグラーゼ阻害剤としての架橋ヘテロ環 Download PDFInfo
- Publication number
- JP2011515412A JP2011515412A JP2011500942A JP2011500942A JP2011515412A JP 2011515412 A JP2011515412 A JP 2011515412A JP 2011500942 A JP2011500942 A JP 2011500942A JP 2011500942 A JP2011500942 A JP 2011500942A JP 2011515412 A JP2011515412 A JP 2011515412A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- hydroxy
- methyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *OCC(CC1)OCC1=O Chemical compound *OCC(CC1)OCC1=O 0.000 description 7
- WSDQKZFAVSJGHU-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCF)=O Chemical compound CC(C)(C)OC(N(C)CCF)=O WSDQKZFAVSJGHU-UHFFFAOYSA-N 0.000 description 1
- IAVATLFZOHRTLU-UHFFFAOYSA-N CC(C)(C)[S+](C)OCC(CC1)CCC1(C#N)OCCO Chemical compound CC(C)(C)[S+](C)OCC(CC1)CCC1(C#N)OCCO IAVATLFZOHRTLU-UHFFFAOYSA-N 0.000 description 1
- LTKJSDFLXHVZEJ-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)OCC(CC1)CCC1(C(NO)=N)OCCO Chemical compound CC(C)(C)[Si+](C)(C)OCC(CC1)CCC1(C(NO)=N)OCCO LTKJSDFLXHVZEJ-UHFFFAOYSA-N 0.000 description 1
- YZOFMZMHHKPYDO-JFECSRQRSA-N CC(N(CC(C1)(F)F)[C@@H]1C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(C)c1F)=O)=C2O)=O)=O Chemical compound CC(N(CC(C1)(F)F)[C@@H]1C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(C)c1F)=O)=C2O)=O)=O YZOFMZMHHKPYDO-JFECSRQRSA-N 0.000 description 1
- DHSGXTSNBKZEGG-WISQGXBXSA-N CC(N(C[C@H](C1)OC)C1C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CC(N(C[C@H](C1)OC)C1C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O DHSGXTSNBKZEGG-WISQGXBXSA-N 0.000 description 1
- CMJMDHICGHNWPI-NDGKPOTDSA-N CC(N[C@H](CC1)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O)=O Chemical compound CC(N[C@H](CC1)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O)=O CMJMDHICGHNWPI-NDGKPOTDSA-N 0.000 description 1
- AFWOJCFAHCWXHA-LDADJPATSA-N CCOC(/C=C(\C(OCC)=O)/ONC(C1(COC(CO)CC1)NC(OCc1ccccc1)=O)=N)=O Chemical compound CCOC(/C=C(\C(OCC)=O)/ONC(C1(COC(CO)CC1)NC(OCc1ccccc1)=O)=N)=O AFWOJCFAHCWXHA-LDADJPATSA-N 0.000 description 1
- PSADNECHGXKQOE-UHFFFAOYSA-N CCOC(C(N=C(C(C1)(COC1CC1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O Chemical compound CCOC(C(N=C(C(C1)(COC1CC1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O PSADNECHGXKQOE-UHFFFAOYSA-N 0.000 description 1
- NFMQBJKBENXIGZ-UHFFFAOYSA-N CCOC(C(N=C(C(CC1)(CC1CC1)N)N1C1=O)=C1O)=O Chemical compound CCOC(C(N=C(C(CC1)(CC1CC1)N)N1C1=O)=C1O)=O NFMQBJKBENXIGZ-UHFFFAOYSA-N 0.000 description 1
- QSKCPNYFWDUZRJ-UHFFFAOYSA-N CCOC(C(N=C(C(CC1)(CC1CC1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O Chemical compound CCOC(C(N=C(C(CC1)(CC1CC1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O QSKCPNYFWDUZRJ-UHFFFAOYSA-N 0.000 description 1
- QACDUJHEVPHISW-UHFFFAOYSA-N CCOC(C(N=C(C(CC1)(CC1CC1)NC(OCc2ccccc2)=O)N1C1=O)=C1OCc1ccccc1)=O Chemical compound CCOC(C(N=C(C(CC1)(CC1CC1)NC(OCc2ccccc2)=O)N1C1=O)=C1OCc1ccccc1)=O QACDUJHEVPHISW-UHFFFAOYSA-N 0.000 description 1
- CFGRMFPWXDFIMP-UHFFFAOYSA-N CCOC(C(N=C(C(CC1)(CCC1OS=O)NC(OCc1ccccc1)=O)NC1=O)=C1OS(C)(=O)=O)=O Chemical compound CCOC(C(N=C(C(CC1)(CCC1OS=O)NC(OCc1ccccc1)=O)NC1=O)=C1OS(C)(=O)=O)=O CFGRMFPWXDFIMP-UHFFFAOYSA-N 0.000 description 1
- BBUGBYKBQQYLET-UHFFFAOYSA-N CCOC(C(N=C(C(CC1)(COC1C1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O Chemical compound CCOC(C(N=C(C(CC1)(COC1C1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O BBUGBYKBQQYLET-UHFFFAOYSA-N 0.000 description 1
- YIFONIPZXAUCOI-UHFFFAOYSA-N CCOC(C(N=C(C(CCC1)(CC1C1)OCCO)N1C1=O)=C1O)=O Chemical compound CCOC(C(N=C(C(CCC1)(CC1C1)OCCO)N1C1=O)=C1O)=O YIFONIPZXAUCOI-UHFFFAOYSA-N 0.000 description 1
- QXPXSQWYVXJRFQ-UHFFFAOYSA-N CCOC(C(N=C(C1(COC(CO)CC1)NC(OCc1ccccc1)=O)NC1=O)=C1O)=O Chemical compound CCOC(C(N=C(C1(COC(CO)CC1)NC(OCc1ccccc1)=O)NC1=O)=C1O)=O QXPXSQWYVXJRFQ-UHFFFAOYSA-N 0.000 description 1
- PDTUJGLXHJWRLE-UHFFFAOYSA-N CN(C)C(C(NC(C1)(COC1CCN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(C1)(COC1CCN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O PDTUJGLXHJWRLE-UHFFFAOYSA-N 0.000 description 1
- FVDRBCOHTSYFFM-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc(c(F)c1)Br)c1Br)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc(c(F)c1)Br)c1Br)=O)=C2O)=O)=O FVDRBCOHTSYFFM-UHFFFAOYSA-N 0.000 description 1
- JTSSWADUMFWERS-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)c(C(F)(F)F)cc1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)c(C(F)(F)F)cc1F)=O)=C2O)=O)=O JTSSWADUMFWERS-UHFFFAOYSA-N 0.000 description 1
- TZGAYEAQNRYYRH-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(C(F)(F)F)c1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(C(F)(F)F)c1F)=O)=C2O)=O)=O TZGAYEAQNRYYRH-UHFFFAOYSA-N 0.000 description 1
- OZTNYZPSQUMTAM-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc1ccccc1)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc1ccccc1)=O)=C2O)=O)=O OZTNYZPSQUMTAM-UHFFFAOYSA-N 0.000 description 1
- JLCZATHHKMWVII-UHFFFAOYSA-N CN(C)C(C(OCCNC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(OCCNC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O JLCZATHHKMWVII-UHFFFAOYSA-N 0.000 description 1
- NLSOWOAQSMHECD-UHFFFAOYSA-N CN(CC1OCCC1)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(CC1OCCC1)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O NLSOWOAQSMHECD-UHFFFAOYSA-N 0.000 description 1
- QIMDZFIZOOJIBX-UHFFFAOYSA-N COC(C1)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound COC(C1)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O QIMDZFIZOOJIBX-UHFFFAOYSA-N 0.000 description 1
- CRZXJJXPVSJYCD-UHFFFAOYSA-N COCCN(CC1)CCN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound COCCN(CC1)CCN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O CRZXJJXPVSJYCD-UHFFFAOYSA-N 0.000 description 1
- PSSMFMZCZXVWGA-UHFFFAOYSA-N CS(N(CCC1)C1C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)(=O)=O Chemical compound CS(N(CCC1)C1C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)(=O)=O PSSMFMZCZXVWGA-UHFFFAOYSA-N 0.000 description 1
- RUUXVDAELZGGJB-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CC1CC1)NC(C(N(C)C)=O)=O)N1C1=O)=C1OCc1ccccc1)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CC1CC1)NC(C(N(C)C)=O)=O)N1C1=O)=C1OCc1ccccc1)=O)cc1)c1F RUUXVDAELZGGJB-UHFFFAOYSA-N 0.000 description 1
- KLBONGSBWPFKRL-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N(C)C(C(N(C)CCOC)=O)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N(C)C(C(N(C)CCOC)=O)=O)N1C1=O)=C1O)=O)cc1)c1F KLBONGSBWPFKRL-UHFFFAOYSA-N 0.000 description 1
- NCWFVXFAXZICFL-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N/C(/NC)=N/C#N)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N/C(/NC)=N/C#N)N1C1=O)=C1O)=O)cc1)c1F NCWFVXFAXZICFL-UHFFFAOYSA-N 0.000 description 1
- DRNPSHLEJPOVJC-YOUJDTTRSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(C(C[C@@H](C2)OC)N2C(c2ncc[n]2C)=O)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(C(C[C@@H](C2)OC)N2C(c2ncc[n]2C)=O)=O)N1C1=O)=C1O)=O)cc1)c1F DRNPSHLEJPOVJC-YOUJDTTRSA-N 0.000 description 1
- XRVCGKHNNQWAIL-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(C(N(C)CCOC)=O)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(C(N(C)CCOC)=O)=O)N1C1=O)=C1O)=O)cc1)c1F XRVCGKHNNQWAIL-UHFFFAOYSA-N 0.000 description 1
- KIUZUJUEVWJQRX-UHFFFAOYSA-N Cc1c(C(NC(CC2)(CCC2CN2C3=O)C2=NC(C(NCc(cc2)ccc2F)=O)=C3O)=O)[o]cn1 Chemical compound Cc1c(C(NC(CC2)(CCC2CN2C3=O)C2=NC(C(NCc(cc2)ccc2F)=O)=C3O)=O)[o]cn1 KIUZUJUEVWJQRX-UHFFFAOYSA-N 0.000 description 1
- DUVSZYPPFULOTQ-UHFFFAOYSA-N Cc1c(CNC(C(N=C(C(CC2)(CCC2C2)NC(C(N(C)C)=O)=O)N2C2=O)=C2O)=O)ncc(F)c1 Chemical compound Cc1c(CNC(C(N=C(C(CC2)(CCC2C2)NC(C(N(C)C)=O)=O)N2C2=O)=C2O)=O)ncc(F)c1 DUVSZYPPFULOTQ-UHFFFAOYSA-N 0.000 description 1
- ZUVXKVMCYIVAFC-UHFFFAOYSA-N Cc1cc(CNC(C(N=C(C(CC2)(CCC2C2)NC(c3nnccc3)=O)N2C2=O)=C2O)=O)ccc1F Chemical compound Cc1cc(CNC(C(N=C(C(CC2)(CCC2C2)NC(c3nnccc3)=O)N2C2=O)=C2O)=O)ccc1F ZUVXKVMCYIVAFC-UHFFFAOYSA-N 0.000 description 1
- UASQDNHYROZFQS-UHFFFAOYSA-N NC(C(N=C(C(CC1)(COC1C1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O Chemical compound NC(C(N=C(C(CC1)(COC1C1)NC(OCc2ccccc2)=O)N1C1=O)=C1O)=O UASQDNHYROZFQS-UHFFFAOYSA-N 0.000 description 1
- XUYHFYZAEAUBDY-UHFFFAOYSA-N NC(COC(C1)CN2C3=O)C1CC2=NC(C(N)=O)=C3O Chemical compound NC(COC(C1)CN2C3=O)C1CC2=NC(C(N)=O)=C3O XUYHFYZAEAUBDY-UHFFFAOYSA-N 0.000 description 1
- VRSKZZIXPDVEFN-UHFFFAOYSA-N NCc(cc1)cc(C#N)c1F Chemical compound NCc(cc1)cc(C#N)c1F VRSKZZIXPDVEFN-UHFFFAOYSA-N 0.000 description 1
- DBCIDXBUENCDAD-UHFFFAOYSA-N OC(C1)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound OC(C1)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O DBCIDXBUENCDAD-UHFFFAOYSA-N 0.000 description 1
- RFXLAUDCFBPSME-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CC2CC2)NC(OCc3ccccc3)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CC2CC2)NC(OCc3ccccc3)=O)N2C1=O RFXLAUDCFBPSME-UHFFFAOYSA-N 0.000 description 1
- AIUQRLQMVWINDY-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCC3F)=O)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCC3F)=O)=O)N2C1=O AIUQRLQMVWINDY-UHFFFAOYSA-N 0.000 description 1
- ORQKXFPPKGYWKR-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N3CCNCC3)=O)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N3CCNCC3)=O)=O)N2C1=O ORQKXFPPKGYWKR-UHFFFAOYSA-N 0.000 description 1
- DBJBJJATLGKWQF-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(NC(c3ccccc3)=O)=S)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(NC(c3ccccc3)=O)=S)N2C1=O DBJBJJATLGKWQF-UHFFFAOYSA-N 0.000 description 1
- KQULNRLGKUTZFQ-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(c3cc(OCC(F)(F)F)ncc3)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(c3cc(OCC(F)(F)F)ncc3)=O)N2C1=O KQULNRLGKUTZFQ-UHFFFAOYSA-N 0.000 description 1
- RPOCHGCJTZOZDK-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(c3ccncc3)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(c3ccncc3)=O)N2C1=O RPOCHGCJTZOZDK-UHFFFAOYSA-N 0.000 description 1
- CEKRLLCESSAGOL-UHFFFAOYSA-N OCCC(C1)OCC1OCc1ccccc1 Chemical compound OCCC(C1)OCC1OCc1ccccc1 CEKRLLCESSAGOL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3772908P | 2008-03-19 | 2008-03-19 | |
| US61/037,729 | 2008-03-19 | ||
| US12/406,268 | 2009-03-18 | ||
| US12/406,268 US8129398B2 (en) | 2008-03-19 | 2009-03-18 | HIV integrase inhibitors |
| PCT/US2009/037596 WO2009117540A1 (en) | 2008-03-19 | 2009-03-19 | Bridged heterocycles as hiv integrase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515412A true JP2011515412A (ja) | 2011-05-19 |
| JP2011515412A5 JP2011515412A5 (enExample) | 2012-05-10 |
Family
ID=40863725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011500942A Pending JP2011515412A (ja) | 2008-03-19 | 2009-03-19 | Ｈｉｖインテグラーゼ阻害剤としての架橋ヘテロ環 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8129398B2 (enExample) |
| EP (1) | EP2280981B8 (enExample) |
| JP (1) | JP2011515412A (enExample) |
| KR (1) | KR20100137522A (enExample) |
| CN (1) | CN102036996A (enExample) |
| AU (1) | AU2009225577A1 (enExample) |
| BR (1) | BRPI0910307A2 (enExample) |
| CA (1) | CA2718950A1 (enExample) |
| CO (1) | CO6331439A2 (enExample) |
| EA (1) | EA201001508A1 (enExample) |
| IL (1) | IL208068A0 (enExample) |
| MX (1) | MX2010009995A (enExample) |
| NZ (1) | NZ588031A (enExample) |
| WO (1) | WO2009117540A1 (enExample) |
| ZA (1) | ZA201006589B (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018529714A (ja) * | 2015-09-30 | 2018-10-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のための化合物および組合せ物 |
| JP2022526895A (ja) * | 2019-03-22 | 2022-05-27 | ギリアード サイエンシーズ， インコーポレイテッド | 有橋三環式カルバモイルピリドン化合物およびその薬学的使用 |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| US11697652B2 (en) | 2020-02-24 | 2023-07-11 | Gilead Sciences, Inc. | Tetracyclic compounds and uses thereof |
| US12421235B2 (en) | 2020-09-30 | 2025-09-23 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120022045A1 (en) * | 2009-01-28 | 2012-01-26 | Shankar Venkatraman | Bridged compounds as hiv integrase inhibitors |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
| EP2603514B1 (en) | 2010-08-10 | 2018-07-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2012077221A1 (ja) * | 2010-12-10 | 2012-06-14 | アグロカネショウ株式会社 | ３-アミノオキサリルアミノベンズアミド誘導体及びこれを有効成分とする殺虫、殺ダニ剤 |
| US8846659B2 (en) | 2010-12-10 | 2014-09-30 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8835411B2 (en) * | 2010-12-10 | 2014-09-16 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| CN102675305B (zh) * | 2011-03-08 | 2014-11-12 | 中国科学院上海药物研究所 | 一类咪唑并吡啶类化合物及其制备方法和用途 |
| US9012491B2 (en) | 2011-08-31 | 2015-04-21 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2014008636A1 (en) * | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US8906929B2 (en) * | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| JP2016509594A (ja) | 2013-01-04 | 2016-03-31 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | ボロン酸誘導体及びその治療的使用 |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| AU2014204046B2 (en) | 2013-01-04 | 2017-02-23 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| KR102194745B1 (ko) | 2013-03-13 | 2020-12-24 | 포르마 세라퓨틱스 인크. | Ｆａｓｎ 억제용 신규 화합물 및 조성물 |
| EP2970297A1 (en) * | 2013-03-14 | 2016-01-20 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| PL3019503T3 (pl) | 2013-07-12 | 2018-01-31 | Gilead Sciences Inc | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| CN103601613B (zh) * | 2013-11-19 | 2015-07-08 | 浙江林江化工股份有限公司 | 一种3,4,5-三氟溴苯的制备方法 |
| WO2015096651A1 (en) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
| US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| RS59488B1 (sr) | 2014-05-05 | 2019-12-31 | Rempex Pharmaceuticals Inc | Sinteza boronatnih soli i njihove upotrebe |
| MX2016015093A (es) | 2014-05-19 | 2017-03-27 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y sus usos terapeuticos. |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| EA201692301A1 (ru) | 2014-07-01 | 2017-06-30 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
| US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016154081A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3277691B1 (en) | 2015-04-02 | 2019-01-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| EP3313852B1 (en) | 2015-06-25 | 2021-01-20 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| EP3478693B1 (en) | 2016-06-30 | 2021-07-21 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| JP7377545B2 (ja) | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ， インコーポレイテッド | ボロン酸誘導体およびその合成 |
| CA3097127A1 (en) | 2018-04-20 | 2019-10-24 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3873214A4 (en) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006513200A (ja) * | 2002-12-27 | 2006-04-20 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ＨＩＶインテグラーゼ阻害薬として有用なテトラヒドロ−４Ｈ−ピリド［１，２−ａ］ピリミジン類および関連する化合物 |
| WO2006103399A1 (en) * | 2005-03-31 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| WO2007027754A1 (en) * | 2005-08-31 | 2007-03-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as hiv integrase inhibitors |
| JP2008501018A (ja) * | 2004-05-28 | 2008-01-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7173022B2 (en) * | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) * | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) * | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| WO2006121831A2 (en) | 2005-05-10 | 2006-11-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US7897592B2 (en) * | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) * | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7897593B2 (en) * | 2006-05-30 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7763630B2 (en) * | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20120022045A1 (en) * | 2009-01-28 | 2012-01-26 | Shankar Venkatraman | Bridged compounds as hiv integrase inhibitors |
-
2009
- 2009-03-18 US US12/406,268 patent/US8129398B2/en active Active
- 2009-03-19 JP JP2011500942A patent/JP2011515412A/ja active Pending
- 2009-03-19 EA EA201001508A patent/EA201001508A1/ru unknown
- 2009-03-19 EP EP09722517.1A patent/EP2280981B8/en not_active Not-in-force
- 2009-03-19 KR KR1020107023261A patent/KR20100137522A/ko not_active Withdrawn
- 2009-03-19 NZ NZ588031A patent/NZ588031A/en not_active IP Right Cessation
- 2009-03-19 CA CA2718950A patent/CA2718950A1/en not_active Abandoned
- 2009-03-19 BR BRPI0910307A patent/BRPI0910307A2/pt not_active IP Right Cessation
- 2009-03-19 WO PCT/US2009/037596 patent/WO2009117540A1/en not_active Ceased
- 2009-03-19 CN CN2009801183261A patent/CN102036996A/zh active Pending
- 2009-03-19 MX MX2010009995A patent/MX2010009995A/es not_active Application Discontinuation
- 2009-03-19 AU AU2009225577A patent/AU2009225577A1/en not_active Abandoned
-
2010
- 2010-09-07 IL IL208068A patent/IL208068A0/en unknown
- 2010-09-14 ZA ZA2010/06589A patent/ZA201006589B/en unknown
- 2010-09-16 CO CO10115016A patent/CO6331439A2/es not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006513200A (ja) * | 2002-12-27 | 2006-04-20 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ＨＩＶインテグラーゼ阻害薬として有用なテトラヒドロ−４Ｈ−ピリド［１，２−ａ］ピリミジン類および関連する化合物 |
| JP2008501018A (ja) * | 2004-05-28 | 2008-01-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 |
| WO2006103399A1 (en) * | 2005-03-31 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| WO2007027754A1 (en) * | 2005-08-31 | 2007-03-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as hiv integrase inhibitors |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018529714A (ja) * | 2015-09-30 | 2018-10-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のための化合物および組合せ物 |
| JP2022526895A (ja) * | 2019-03-22 | 2022-05-27 | ギリアード サイエンシーズ， インコーポレイテッド | 有橋三環式カルバモイルピリドン化合物およびその薬学的使用 |
| JP2023033640A (ja) * | 2019-03-22 | 2023-03-10 | ギリアード サイエンシーズ， インコーポレイテッド | 有橋三環式カルバモイルピリドン化合物およびその薬学的使用 |
| JP7265647B2 (ja) | 2019-03-22 | 2023-04-26 | ギリアード サイエンシーズ， インコーポレイテッド | 有橋三環式カルバモイルピリドン化合物およびその薬学的使用 |
| US12227520B2 (en) | 2019-03-22 | 2025-02-18 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| JP7710476B2 (ja) | 2019-03-22 | 2025-07-18 | ギリアード サイエンシーズ， インコーポレイテッド | 有橋三環式カルバモイルピリドン化合物およびその薬学的使用 |
| US11697652B2 (en) | 2020-02-24 | 2023-07-11 | Gilead Sciences, Inc. | Tetracyclic compounds and uses thereof |
| US12421235B2 (en) | 2020-09-30 | 2025-09-23 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| US11897892B2 (en) | 2021-01-19 | 2024-02-13 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| US12187734B2 (en) | 2021-01-19 | 2025-01-07 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| IL208068A0 (en) | 2010-12-30 |
| US20090253677A1 (en) | 2009-10-08 |
| NZ588031A (en) | 2011-12-22 |
| CN102036996A (zh) | 2011-04-27 |
| KR20100137522A (ko) | 2010-12-30 |
| AU2009225577A1 (en) | 2009-09-24 |
| CO6331439A2 (es) | 2011-10-20 |
| EP2280981B1 (en) | 2014-04-23 |
| CA2718950A1 (en) | 2009-09-24 |
| EP2280981B8 (en) | 2014-09-17 |
| MX2010009995A (es) | 2010-09-30 |
| BRPI0910307A2 (pt) | 2019-09-24 |
| US8129398B2 (en) | 2012-03-06 |
| WO2009117540A1 (en) | 2009-09-24 |
| EP2280981A1 (en) | 2011-02-09 |
| EA201001508A1 (ru) | 2011-04-29 |
| ZA201006589B (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515412A (ja) | Ｈｉｖインテグラーゼ阻害剤としての架橋ヘテロ環 | |
| AU2017290755B2 (en) | Diazepinone derivatives and their use in the treatment of hepatitis B infections | |
| JP6629419B2 (ja) | Ｍｃｌ−１タンパク質を阻害する化合物 | |
| JP6550083B2 (ja) | Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体 | |
| US10987359B2 (en) | Oxadiazepinone derivatives and methods of treating hepatitis B infections | |
| US7473688B2 (en) | Indolobenzazepine HCV NS5B inhibitors | |
| US8940912B2 (en) | 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid | |
| TWI890869B (zh) | α-D-吡喃半乳糖苷之螺衍生物 | |
| EA016614B1 (ru) | Соединения для лечения гепатита с | |
| WO2009067108A1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| JP2022514437A (ja) | 治療用化合物 | |
| AU2018291688A1 (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | |
| JP2016516692A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| US9273067B2 (en) | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | |
| TW201416363A (zh) | Ｃ型肝炎病毒抑制劑 | |
| JP2016512501A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP2009256323A (ja) | ピラゾロピリミジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120316 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120316 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130917 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140507 |